← Eichor
Study identifier: NCT06982820 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia

Condition: Depressive Disorder, Major  ·  Sponsor: GrayMatters Health Ltd.

PhaseNA
Planned participants170
Who can joinAll sexes, 22 Years to 75 Years
Healthy volunteersNo

About this study

The purpose of this research is to learn more about a new treatment for individuals with Major Depressive Disorder (MDD) with heightened symptoms of anhedonia (i.e. loss of pleasure or interest in activities). The treatment is called Prism, and it is a software device intended for a novel form of neurofeedback training to be used in a clinic setting. During this study, the subject will use different techniques to measure brain activities, including magnetic resonance imaging (MRI) and electroencephalography (EEG).

This description comes directly from the study's public registry record.

Talk to the study team

Adar Shani, MSc  ·  +972-54-2347770  ·  adar@graymatters-health.com

Jennifer Yarden, PhD  ·  +972-52-4897823  ·  jennifer@graymatters-health.com

Always discuss trial participation with your own doctor first.

Locations (3)

Butler HospitalProvidence, Rhode Island, United StatesRecruiting
Houston Center For Advanced Psychiatric TreatmentHouston, Texas, United StatesRecruiting
Sheba Medical CenterRamat Gan, IsraelRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06982820